Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$160.38
0.0%
$171.83
$130.96
$182.89
$283.21B0.615.64 million shs3.57 million shs
Mastercard Incorporated stock logo
MA
Mastercard
$455.53
+0.2%
$468.16
$357.85
$490.00
$424.96B1.082.46 million shs1.97 million shs
Morgan Stanley stock logo
MS
Morgan Stanley
$98.13
+2.6%
$90.88
$69.42
$98.26
$159.62B1.418.39 million shs6.77 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-0.01%-0.29%-5.73%-7.85%+9.53%
Mastercard Incorporated stock logo
MA
Mastercard
+0.12%+3.27%-3.52%-0.51%+19.08%
Morgan Stanley stock logo
MS
Morgan Stanley
+2.60%+5.91%+4.30%+14.25%+17.21%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.331 of 5 stars
1.43.04.23.92.72.51.9
Mastercard Incorporated stock logo
MA
Mastercard
4.7806 of 5 stars
2.53.03.33.02.42.53.1
Morgan Stanley stock logo
MS
Morgan Stanley
4.5851 of 5 stars
2.23.03.32.43.12.52.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.77
Moderate Buy$174.318.68% Upside
Mastercard Incorporated stock logo
MA
Mastercard
2.96
Moderate Buy$496.278.94% Upside
Morgan Stanley stock logo
MS
Morgan Stanley
2.42
Hold$98.300.18% Upside

Current Analyst Ratings

Latest ABBV, MS, and MA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2024
Mastercard Incorporated stock logo
MA
Mastercard
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$549.00 ➝ $530.00
5/2/2024
Mastercard Incorporated stock logo
MA
Mastercard
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$536.00 ➝ $524.00
5/2/2024
Mastercard Incorporated stock logo
MA
Mastercard
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$520.00 ➝ $510.00
5/2/2024
Mastercard Incorporated stock logo
MA
Mastercard
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$480.00 ➝ $478.00
4/30/2024
Morgan Stanley stock logo
MS
Morgan Stanley
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$101.00 ➝ $105.00
4/29/2024
AbbVie Inc. stock logo
ABBV
AbbVie
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$195.00 ➝ $187.00
4/29/2024
AbbVie Inc. stock logo
ABBV
AbbVie
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$195.00 ➝ $180.00
4/19/2024
Morgan Stanley stock logo
MS
Morgan Stanley
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$100.00 ➝ $102.00
4/18/2024
Mastercard Incorporated stock logo
MA
Mastercard
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$525.00 ➝ $545.00
4/18/2024
Morgan Stanley stock logo
MS
Morgan Stanley
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
4/18/2024
Morgan Stanley stock logo
MS
Morgan Stanley
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$115.00 ➝ $118.00
(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$54.40B5.21$15.48 per share10.36$5.78 per share27.75
Mastercard Incorporated stock logo
MA
Mastercard
$25.10B16.93$15.43 per share29.53$7.47 per share60.98
Morgan Stanley stock logo
MS
Morgan Stanley
$96.19B1.66$8.82 per share11.13$55.58 per share1.77

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.86B$3.3747.5913.302.0711.02%165.18%14.40%7/25/2024 (Estimated)
Mastercard Incorporated stock logo
MA
Mastercard
$11.20B$12.5836.2127.761.7446.09%183.70%29.37%7/25/2024 (Estimated)
Morgan Stanley stock logo
MS
Morgan Stanley
$9.09B$5.4917.8712.661.769.57%10.87%0.85%7/16/2024 (Estimated)

Latest ABBV, MS, and MA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/3/2024Q1 24
AbbVie Inc. stock logo
ABBV
AbbVie
$2.26$2.31+$0.05$3.85$11.93 billion$12.31 billion      
5/1/2024Q1 2024
Mastercard Incorporated stock logo
MA
Mastercard
$3.22$3.31+$0.09$3.40$6.34 billion$6.35 billion    
4/16/2024Q1 24
Morgan Stanley stock logo
MS
Morgan Stanley
$1.69$2.02+$0.33$2.02$14.42 billion$15.14 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.203.87%+7.84%183.98%52 Years
Mastercard Incorporated stock logo
MA
Mastercard
$2.640.58%+12.53%20.99%12 Years
Morgan Stanley stock logo
MS
Morgan Stanley
$3.403.46%+32.41%61.93%3 Years

Latest ABBV, MS, and MA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/15/2024
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.553.54%4/12/20244/15/20245/15/2024
4/16/2024
Morgan Stanley stock logo
MS
Morgan Stanley
quarterly$0.853.8%4/29/20244/30/20245/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
5.02
0.87
0.76
Mastercard Incorporated stock logo
MA
Mastercard
1.86
1.09
1.09
Morgan Stanley stock logo
MS
Morgan Stanley
2.89
0.75
0.75

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Mastercard Incorporated stock logo
MA
Mastercard
97.28%
Morgan Stanley stock logo
MS
Morgan Stanley
84.19%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.25%
Mastercard Incorporated stock logo
MA
Mastercard
0.13%
Morgan Stanley stock logo
MS
Morgan Stanley
0.24%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.77 billionOptionable
Mastercard Incorporated stock logo
MA
Mastercard
33,400932.89 million931.68 millionOptionable
Morgan Stanley stock logo
MS
Morgan Stanley
80,0001.63 billion1.62 billionOptionable

ABBV, MS, and MA Headlines

SourceHeadline
National Pension Service Purchases 40,583 Shares of Morgan Stanley (NYSE:MS)National Pension Service Purchases 40,583 Shares of Morgan Stanley (NYSE:MS)
marketbeat.com - May 9 at 1:05 PM
Everpar Advisors LLC Acquires Shares of 9,665 Morgan Stanley (NYSE:MS)Everpar Advisors LLC Acquires Shares of 9,665 Morgan Stanley (NYSE:MS)
marketbeat.com - May 8 at 9:32 PM
Morgan Stanley now expects the Fed to start rate cuts in SeptemberMorgan Stanley now expects the Fed to start rate cuts in September
msn.com - May 8 at 7:20 PM
Morgan Stanley (MS) Could Be a Great ChoiceMorgan Stanley (MS) Could Be a Great Choice
zacks.com - May 8 at 12:46 PM
3 Investment Banks to Buy on Flourishing Industry Prospects3 Investment Banks to Buy on Flourishing Industry Prospects
zacks.com - May 8 at 9:10 AM
Indias Rail Freight Growth: Morgan Stanleys Take on this “Undervalued Stock”India's Rail Freight Growth: Morgan Stanley's Take on this “Undervalued Stock”
au.investing.com - May 8 at 8:04 AM
Morgan Stanley now expects the Federal Reserve to start rate cuts in SeptemberMorgan Stanley now expects the Federal Reserve to start rate cuts in September
msn.com - May 8 at 8:04 AM
Morgan Stanleys Analysis of Indian Stock Market TrendsMorgan Stanley's Analysis of Indian Stock Market Trends
msn.com - May 8 at 8:04 AM
Beyond Market Price: Uncovering Morgan Stanleys Intrinsic ValueBeyond Market Price: Uncovering Morgan Stanley's Intrinsic Value
finance.yahoo.com - May 7 at 10:03 PM
TSMC: Morgan Stanley hikes PT on Arm AI CPU boostTSMC: Morgan Stanley hikes PT on Arm AI CPU boost
msn.com - May 7 at 10:03 PM
Morgan Stanley (NYSE:MS) Reaches New 12-Month High at $95.92Morgan Stanley (NYSE:MS) Reaches New 12-Month High at $95.92
marketbeat.com - May 7 at 5:14 PM
Market Whales and Their Recent Bets on Morgan Stanley OptionsMarket Whales and Their Recent Bets on Morgan Stanley Options
benzinga.com - May 7 at 5:03 PM
Morgan Stanley CIO Cites Humbling Business Behind Wrong Forecasts, Gives Up Predicting S&P 500 As One Division Faces SEC ProbeMorgan Stanley CIO Cites 'Humbling Business' Behind Wrong Forecasts, Gives Up Predicting S&P 500 As One Division Faces SEC Probe
finance.yahoo.com - May 7 at 5:03 PM
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Morgan Stanley for potential violations of federal securities lawsWolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Morgan Stanley for potential violations of federal securities laws
prnewswire.com - May 7 at 3:05 PM
This major factor will crush bond yields later in the year, says Morgan Stanley - MarketWatchThis major factor will crush bond yields later in the year, says Morgan Stanley - MarketWatch
news.google.com - May 7 at 9:03 AM
Merit Financial Group LLC Has $832,000 Position in Morgan Stanley (NYSE:MS)Merit Financial Group LLC Has $832,000 Position in Morgan Stanley (NYSE:MS)
marketbeat.com - May 7 at 8:26 AM
Titagarh Rail shares jump 9% after Morgan Stanley initiates with overweight ratingTitagarh Rail shares jump 9% after Morgan Stanley initiates with overweight rating
economictimes.indiatimes.com - May 7 at 3:34 AM
Whataburger Returns to Loan Market With $2.7 Billion DealWhataburger Returns to Loan Market With $2.7 Billion Deal
finance.yahoo.com - May 7 at 1:33 AM
Rockefeller Capital Management Hires $1.1 Billion Advisor Team From Morgan StanleyRockefeller Capital Management Hires $1.1 Billion Advisor Team From Morgan Stanley
msn.com - May 6 at 3:32 PM
Morgan Stanley Gets New Tech Team Leader - Veteran Crystal Zhu From JPMorganMorgan Stanley Gets New Tech Team Leader - Veteran Crystal Zhu From JPMorgan
finance.yahoo.com - May 6 at 3:32 PM
EH Stock Alert: Morgan Stanley Says Flying Car Maker EHang Has 60% Upside PotentialEH Stock Alert: Morgan Stanley Says Flying Car Maker EHang Has 60% Upside Potential
investorplace.com - May 6 at 2:41 PM
Heres Why Morgan Stanley (MS) Stock is a Must Buy Right NowHere's Why Morgan Stanley (MS) Stock is a Must Buy Right Now
zacks.com - May 6 at 2:01 PM
Morgan Stanley warns about an uncertain macro backdropMorgan Stanley warns about an 'uncertain macro backdrop'
msn.com - May 6 at 10:32 AM
Morgan Stanley Private Credit Leads Strategic Growth Capital Investment In Guardian Dentistry PartnersMorgan Stanley Private Credit Leads Strategic Growth Capital Investment In Guardian Dentistry Partners
businesswire.com - May 6 at 9:00 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AbbVie logo

AbbVie

NYSE:ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Mastercard logo

Mastercard

NYSE:MA
Mastercard Incorporated, a technology company, provides transaction processing and other payment-related products and services in the United States and internationally. The company offers integrated products and value-added services for account holders, merchants, financial institutions, digital partners, businesses, governments, and other organizations, such as programs that enable issuers to provide consumers with credits to defer payments; payment products and solutions that allow its customers to access funds in deposit and other accounts; prepaid programs services; and commercial credit, debit, and prepaid payment products and solutions. It also provides solutions that enable businesses or governments to make payments to businesses, including Virtual Card Number, which is generated dynamically from a physical card and leverages the credit limit of the funding account; a platform to optimize supplier payment enablement campaigns for financial institutions; and treasury intelligence platform that offers corporations with recommendations to enhance working capital performance and accelerate spend on cards. In addition, the company offers Mastercard Send, which partners with digital messaging and payment platforms to enable consumers to send money directly within applications to other consumers; and Mastercard Cross-Border Services enables a range of payment flows through a distribution network with a single point of access to send and receive money globally through various channels, including bank accounts, mobile wallets, cards, and cash payouts. Further, it provides cyber and intelligence solutions; insights and analytics, consulting, marketing, loyalty, processing, and payment gateway solutions for e-commerce merchants; and open banking and digital identity services. The company offers payment solutions and services under the MasterCard, Maestro, and Cirrus name. Mastercard Incorporated was founded in 1966 and is headquartered in Purchase, New York.
Morgan Stanley logo

Morgan Stanley

NYSE:MS
Morgan Stanley, a financial holding company, provides various financial products and services to corporations, governments, financial institutions, and individuals in the Americas, Europe, the Middle East, Africa, and Asia. It operates through Institutional Securities, Wealth Management, and Investment Management segments. The Institutional Securities segment offers capital raising and financial advisory services, including services related to the underwriting of debt, equity, and other securities, as well as advice on mergers and acquisitions, restructurings, real estate, and project finance. This segment also provides equity and fixed income products comprising sales, financing, prime brokerage, and market-making services; foreign exchange and commodities; corporate and commercial real estate loans, commercial mortgage and secured lending facilities, and financing for sales and trading customers, and asset-backed and mortgage lending; and wealth management services, investment, and research services. The Wealth Management segment offers financial advisor-led brokerage, custody, administrative, and investment advisory services; self-directed brokerage services; financial and wealth planning services; workplace services, including stock plan administration; annuity and insurance products; securities-based lending, residential real estate loans, and other lending products; banking; and retirement plan services to individual investors and small to medium-sized businesses and institutions. The Investment Management segment provides equity, fixed income, alternatives and solutions, and liquidity and overlay services to benefit/defined contribution plans, foundations, endowments, government entities, sovereign wealth funds, insurance companies, third-party fund sponsors, corporations, and individuals through institutional and intermediary channels. The company was founded in 1924 and is headquartered in New York, New York.